Carbogen Amcis invests in ADC capacity

Carbogen Amcis invests in ADC capacity

Carbogen Amcis AG has become the latest CMO to invest in antibody drug conjugate (ADC) production.

The firm – a unit of India’s Dishman – set out its ADC plan this week, explaining that it has set up a dedicated clean room and clinical supply suite at its plant in Bubendorf, Switzerland and spent almost $1m (Eur 739,000) to upgrade a sterile manufacturing area at its facility in Riom, France.

News of the investment follows just a few weeks after Carbogen Amcis set up a formal collaboration with St Asaph, Wales-based ADC Biotechnology in a deal designed to meld the latter’s solid phase immobilisation production technology with its manufacturing capacity.

Like most of the contract manufacturing organisations (CMO) that have invested in ADC technology recently – Novasep, Piramal and Lonza to name three – Carbogen Amcis expects the market for this type of product to grow significantly.

When the ADC Biotechnology deal was signed Carbogen Amcis predicted that: "The commercial value of the ADC drug market is projected to reach $5 billion by 2015" and added that "several ADCs are in late-phase trials, with over 60 in pre-clinical testing."

This optimism was echoed by CEO Mark Griffiths for the latest announcement. He cited drugs like Takeda’s Adcetris – which is approved in Europe and the US – Roche’s Kadcyla – cleared in the US and under review in Europe – and Pfizer’s Mylotarg – never approved by the EMA and withdrawn in the US – as key drivers for the investment.

Griffiths said the three drugs “have fueled a growing demand for ADCs and we made the decision to expand our ADC service offer to support customers in the development of next-generation cancer treatments.”

He added that: “We have taken into account customer feedback and market dynamics and are confident that our enhanced infrastructure will enable us to provide our partners in the pharmaceutical industry a needed resource in drug development.”

Carbogen Amcis did not respond to requests for more information ahead of publication.

Related News

Competition not a concern says Carbogen Amcis CEO

Carbogen Amcis CEO: Competition in ADC sector not a concern

Roche to build $208m ADC plant

Roche to build $208m ADC plant to support Kadcyla production

More investment in ADCs - 'warhead' cytotoxic small molecule linked to cancer-targeting mAb

MedImmune looks to 'next generation biologics' with $200m ADC investment

Another day, another ADC investment: SAFC adds ADC capacity

Another day, another ADC investment: SAFC adds commercial-scale capacity

ADCs a big opportunity for Big Pharma say experts

Big Pharma business opportunities driving ADC boom say experts

EC approves Roche's ADC drug Kadcyla

Roche's Kadcyla becomes Europe's second commercialised ADC

Novartis signs third ADC licensing agreement with Immunogen

Novartis signs third ADC licensing agreement with Immunogen this year

Roche and Molecular Partners team over DARPin-drug conjugate technology

Smaller large molecules? Roche invests $62m in DARPin dev deal

Talking ADCs with SAFC, Piramal and Catalent at CPhI Frankfurt

'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI

Takeda licenses Mersana's ADC technology platform

Takeda licenses Fleximar-ADC conjugation and linker tech from Mersana

MacroGenics extends license of Polytherics' Thiobridge ADC tech

MacroGenics extends license of Polytherics' Thiobridge ADC tech

Carbogen Amcis has signed a long-term lease for an ADC unit in Vionnaz, Switzerland

Carbogen Amcis takes over Swiss plant to boost ADC offering

ADC Bio to build Welsh manufacturing site on back of ADC demand

ADC Bio to build Welsh manufacturing site on back of antibody-drug demand

Carbogen Amcis to buy GEA plant in Bubendorf (source Google)

Carbogen Amcis to buy GEA plant and convert it for API production

Image: iStock/scyther5

Pfizer resubmits US and EU application for withdrawn ADC Mylotarg

Carbogen Amcis teams with liposomal delivery tech firm for HP API biz

Carbogen Amcis buys French CMO Creapharm Parenterals

Carbogen Amcis buys French CMO Creapharm Parenterals

New Tech Director: Aesica Offers One-Stop Shop Manufacturing

New Tech Director: Aesica Offers One-Stop Shop Manufacturing

ADC invests in production tech

ADC Bio open to antibody drug conjugate collaborations and CMO takovers

Related Products

See more related products